Characteristics at Baseline and at Adult Height of Patients Treated With vs Not Treated With Biologics During Follow-up
| Variable . | Total (n = 48) . | Treatment With Biologics . | ||
|---|---|---|---|---|
| Biologics (n = 31) . | No Biologics (n = 17) . | P Valuea . | ||
| At baseline | ||||
| Male sex, n (%) | 15 (48.4) | 11 (64.7) | 0.28 | |
| CA (y) | 10.1 (7.3–13.3) | 8.6 (6.8–11.1) | 13.3 (10.3–14.8) | 0.01 |
| Glucocorticoid therapy duration (y) | 4.7 (2.3–7.5) | 4.1 (1.3–4.9) | 8.2 (4.8–10.3) | <0.01 |
| Height (SDS) | −2.9 (−4.4 to −1.6) | −2.5 (−3.6 to −1.3) | −4.2 (−5.0 to −2.9) | 0.03 |
| Bone age (y) (n = 46b) | 8.7 (5.5–10.0) | 7.5 (5.0–9.0) | 10.0 (7.8–11.3) | 0.02 |
| Target height (SDS) (n = 46b) | −0.2 (−1.0 to 0.4) | −0.3 (−1.0 to 0.3) | −0.2 (−0.9 to 0.4) | 0.78 |
| Height − target height (SDS) (n = 46b) | −2.5 (−4.1 to −1.4) | −2.2 (−3.0 to −1.3) | −3.9 (−4.6 to −2.4) | 0.03 |
| Age at biologics initiation (y) | 10.5 (8.6–13.1) | |||
| At adult height | ||||
| GH therapy duration (y) | 6.5 (4.7–8.0) | 7.0 (4.8–8.4) | 5.1 (4.7–6.6) | 0.14 |
| Glucocorticoid therapy duration (y) (n = 47c) | 12.2 (9.0–14.4) | 11.2 (8.6–14.0) | 12.6 (10.0–14.6) | 0.14 |
| CA (y) | 18.1 (17.0–20.1) | 17.9 (17.0–19.0) | 18.5 (17.6–20.8) | 0.25 |
| Bone age (y) (n = 40)d | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 0.47 |
| Adult height (SDS) | −1.7 (−3.9 to −0.1) | −1.5 (−3.0 to 0.1) | −2.6 (−4.2 to −0.4) | 0.16 |
| Corrected adult heighte(SDS) (n = 46b) | −1.3 (−3.0 to −0.2) | −0.9 (−2.3 to −0.1) | −2.0 (−3.7 to −1.0) | 0.08 |
| Height gain from baseline to adult height (SDS) | 1.0 (0.0– 2.2) | 1.0 (0.1–2.0) | 1.0 (−0.2 to 2.5) | 0.84 |
| Favorable growth outcome during GH therapy, n (%)f | 24 (52.2) (n = 46) | 19 (63.3) (n = 30) | 5 (31.3) (n = 16) | 0.06 |
| Variable . | Total (n = 48) . | Treatment With Biologics . | ||
|---|---|---|---|---|
| Biologics (n = 31) . | No Biologics (n = 17) . | P Valuea . | ||
| At baseline | ||||
| Male sex, n (%) | 15 (48.4) | 11 (64.7) | 0.28 | |
| CA (y) | 10.1 (7.3–13.3) | 8.6 (6.8–11.1) | 13.3 (10.3–14.8) | 0.01 |
| Glucocorticoid therapy duration (y) | 4.7 (2.3–7.5) | 4.1 (1.3–4.9) | 8.2 (4.8–10.3) | <0.01 |
| Height (SDS) | −2.9 (−4.4 to −1.6) | −2.5 (−3.6 to −1.3) | −4.2 (−5.0 to −2.9) | 0.03 |
| Bone age (y) (n = 46b) | 8.7 (5.5–10.0) | 7.5 (5.0–9.0) | 10.0 (7.8–11.3) | 0.02 |
| Target height (SDS) (n = 46b) | −0.2 (−1.0 to 0.4) | −0.3 (−1.0 to 0.3) | −0.2 (−0.9 to 0.4) | 0.78 |
| Height − target height (SDS) (n = 46b) | −2.5 (−4.1 to −1.4) | −2.2 (−3.0 to −1.3) | −3.9 (−4.6 to −2.4) | 0.03 |
| Age at biologics initiation (y) | 10.5 (8.6–13.1) | |||
| At adult height | ||||
| GH therapy duration (y) | 6.5 (4.7–8.0) | 7.0 (4.8–8.4) | 5.1 (4.7–6.6) | 0.14 |
| Glucocorticoid therapy duration (y) (n = 47c) | 12.2 (9.0–14.4) | 11.2 (8.6–14.0) | 12.6 (10.0–14.6) | 0.14 |
| CA (y) | 18.1 (17.0–20.1) | 17.9 (17.0–19.0) | 18.5 (17.6–20.8) | 0.25 |
| Bone age (y) (n = 40)d | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 0.47 |
| Adult height (SDS) | −1.7 (−3.9 to −0.1) | −1.5 (−3.0 to 0.1) | −2.6 (−4.2 to −0.4) | 0.16 |
| Corrected adult heighte(SDS) (n = 46b) | −1.3 (−3.0 to −0.2) | −0.9 (−2.3 to −0.1) | −2.0 (−3.7 to −1.0) | 0.08 |
| Height gain from baseline to adult height (SDS) | 1.0 (0.0– 2.2) | 1.0 (0.1–2.0) | 1.0 (−0.2 to 2.5) | 0.84 |
| Favorable growth outcome during GH therapy, n (%)f | 24 (52.2) (n = 46) | 19 (63.3) (n = 30) | 5 (31.3) (n = 16) | 0.06 |
Data are median (IQR) unless stated otherwise.
Data were analyzed using the Mann-Whitney-Wilcoxon test for nonnormally distributed continuous variables.
Data were missing for one male and one female.
Data were missing for one male.
Data were missing for four males and four females.
Adult height SDS − target height SDS.
Favorable growth outcome was defined as a corrected adult height (adult height − target height) ≤ 1.5 SDs.
Characteristics at Baseline and at Adult Height of Patients Treated With vs Not Treated With Biologics During Follow-up
| Variable . | Total (n = 48) . | Treatment With Biologics . | ||
|---|---|---|---|---|
| Biologics (n = 31) . | No Biologics (n = 17) . | P Valuea . | ||
| At baseline | ||||
| Male sex, n (%) | 15 (48.4) | 11 (64.7) | 0.28 | |
| CA (y) | 10.1 (7.3–13.3) | 8.6 (6.8–11.1) | 13.3 (10.3–14.8) | 0.01 |
| Glucocorticoid therapy duration (y) | 4.7 (2.3–7.5) | 4.1 (1.3–4.9) | 8.2 (4.8–10.3) | <0.01 |
| Height (SDS) | −2.9 (−4.4 to −1.6) | −2.5 (−3.6 to −1.3) | −4.2 (−5.0 to −2.9) | 0.03 |
| Bone age (y) (n = 46b) | 8.7 (5.5–10.0) | 7.5 (5.0–9.0) | 10.0 (7.8–11.3) | 0.02 |
| Target height (SDS) (n = 46b) | −0.2 (−1.0 to 0.4) | −0.3 (−1.0 to 0.3) | −0.2 (−0.9 to 0.4) | 0.78 |
| Height − target height (SDS) (n = 46b) | −2.5 (−4.1 to −1.4) | −2.2 (−3.0 to −1.3) | −3.9 (−4.6 to −2.4) | 0.03 |
| Age at biologics initiation (y) | 10.5 (8.6–13.1) | |||
| At adult height | ||||
| GH therapy duration (y) | 6.5 (4.7–8.0) | 7.0 (4.8–8.4) | 5.1 (4.7–6.6) | 0.14 |
| Glucocorticoid therapy duration (y) (n = 47c) | 12.2 (9.0–14.4) | 11.2 (8.6–14.0) | 12.6 (10.0–14.6) | 0.14 |
| CA (y) | 18.1 (17.0–20.1) | 17.9 (17.0–19.0) | 18.5 (17.6–20.8) | 0.25 |
| Bone age (y) (n = 40)d | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 0.47 |
| Adult height (SDS) | −1.7 (−3.9 to −0.1) | −1.5 (−3.0 to 0.1) | −2.6 (−4.2 to −0.4) | 0.16 |
| Corrected adult heighte(SDS) (n = 46b) | −1.3 (−3.0 to −0.2) | −0.9 (−2.3 to −0.1) | −2.0 (−3.7 to −1.0) | 0.08 |
| Height gain from baseline to adult height (SDS) | 1.0 (0.0– 2.2) | 1.0 (0.1–2.0) | 1.0 (−0.2 to 2.5) | 0.84 |
| Favorable growth outcome during GH therapy, n (%)f | 24 (52.2) (n = 46) | 19 (63.3) (n = 30) | 5 (31.3) (n = 16) | 0.06 |
| Variable . | Total (n = 48) . | Treatment With Biologics . | ||
|---|---|---|---|---|
| Biologics (n = 31) . | No Biologics (n = 17) . | P Valuea . | ||
| At baseline | ||||
| Male sex, n (%) | 15 (48.4) | 11 (64.7) | 0.28 | |
| CA (y) | 10.1 (7.3–13.3) | 8.6 (6.8–11.1) | 13.3 (10.3–14.8) | 0.01 |
| Glucocorticoid therapy duration (y) | 4.7 (2.3–7.5) | 4.1 (1.3–4.9) | 8.2 (4.8–10.3) | <0.01 |
| Height (SDS) | −2.9 (−4.4 to −1.6) | −2.5 (−3.6 to −1.3) | −4.2 (−5.0 to −2.9) | 0.03 |
| Bone age (y) (n = 46b) | 8.7 (5.5–10.0) | 7.5 (5.0–9.0) | 10.0 (7.8–11.3) | 0.02 |
| Target height (SDS) (n = 46b) | −0.2 (−1.0 to 0.4) | −0.3 (−1.0 to 0.3) | −0.2 (−0.9 to 0.4) | 0.78 |
| Height − target height (SDS) (n = 46b) | −2.5 (−4.1 to −1.4) | −2.2 (−3.0 to −1.3) | −3.9 (−4.6 to −2.4) | 0.03 |
| Age at biologics initiation (y) | 10.5 (8.6–13.1) | |||
| At adult height | ||||
| GH therapy duration (y) | 6.5 (4.7–8.0) | 7.0 (4.8–8.4) | 5.1 (4.7–6.6) | 0.14 |
| Glucocorticoid therapy duration (y) (n = 47c) | 12.2 (9.0–14.4) | 11.2 (8.6–14.0) | 12.6 (10.0–14.6) | 0.14 |
| CA (y) | 18.1 (17.0–20.1) | 17.9 (17.0–19.0) | 18.5 (17.6–20.8) | 0.25 |
| Bone age (y) (n = 40)d | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 17.0 (16.0–18.0) | 0.47 |
| Adult height (SDS) | −1.7 (−3.9 to −0.1) | −1.5 (−3.0 to 0.1) | −2.6 (−4.2 to −0.4) | 0.16 |
| Corrected adult heighte(SDS) (n = 46b) | −1.3 (−3.0 to −0.2) | −0.9 (−2.3 to −0.1) | −2.0 (−3.7 to −1.0) | 0.08 |
| Height gain from baseline to adult height (SDS) | 1.0 (0.0– 2.2) | 1.0 (0.1–2.0) | 1.0 (−0.2 to 2.5) | 0.84 |
| Favorable growth outcome during GH therapy, n (%)f | 24 (52.2) (n = 46) | 19 (63.3) (n = 30) | 5 (31.3) (n = 16) | 0.06 |
Data are median (IQR) unless stated otherwise.
Data were analyzed using the Mann-Whitney-Wilcoxon test for nonnormally distributed continuous variables.
Data were missing for one male and one female.
Data were missing for one male.
Data were missing for four males and four females.
Adult height SDS − target height SDS.
Favorable growth outcome was defined as a corrected adult height (adult height − target height) ≤ 1.5 SDs.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
